Diphtheria - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Diphtheria - Pipeline Review, H1 2016', provides an overview of the Diphtheria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diphtheria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diphtheria - The report reviews pipeline therapeutics for Diphtheria by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diphtheria therapeutics and enlists all their major and minor projects - The report assesses Diphtheria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diphtheria Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Diphtheria Overview 10 Therapeutics Development 11 Pipeline Products for Diphtheria - Overview 11 Pipeline Products for Diphtheria - Comparative Analysis 12 Diphtheria - Therapeutics under Development by Companies 13 Diphtheria - Therapeutics under Investigation by Universities/Institutes 15 Diphtheria - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Diphtheria - Products under Development by Companies 19 Diphtheria - Products under Investigation by Universities/Institutes 21 Diphtheria - Companies Involved in Therapeutics Development 22 Beijing Minhai Biotechnology Co., Ltd 22 Biological E. Limited 23 Boryung Pharmaceutical Co., Ltd. 24 Daiichi Sankyo Company, Limited 25 GlaxoSmithKline Plc 26 Green Cross Corporation 27 Indian Immunologicals Limited 28 LG Life Science LTD. 29 Panacea Biotec Limited 30 Prometheon Pharma, LLC 31 Sanofi Pasteur SA 32 Serum Institute of India Limited 33 Sinovac Biotech Ltd. 34 Zydus Cadila Healthcare Limited 35 Diphtheria - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Drug Profiles 44 (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole-cell) + tetanus) (pentavalent) vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 (diphtheria + tetanus) vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 diphtheria vaccine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Eupenta - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 GC-1107 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 GC-3111A - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 LBVD - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 VN-0103 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 VN-0105 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Diphtheria - Recent Pipeline Updates 77 Diphtheria - Dormant Projects 79 Diphtheria - Discontinued Products 80 Diphtheria - Product Development Milestones 81 Featured News & Press Releases 81 Mar 21, 2016: BE Receives an Order from Govt. of India to Supply Liquid Pentavalent Vaccines 81 Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta 81 Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 82 Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 82 Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age 83 Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 83 Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 84 Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 85 Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion from European Medicines Agency 85 Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 87 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 88 Disclaimer 89
List of Tables
Number of Products under Development for Diphtheria, H1 2016 11 Number of Products under Development for Diphtheria - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 22 Diphtheria - Pipeline by Biological E. Limited, H1 2016 23 Diphtheria - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 24 Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 25 Diphtheria - Pipeline by GlaxoSmithKline Plc, H1 2016 26 Diphtheria - Pipeline by Green Cross Corporation, H1 2016 27 Diphtheria - Pipeline by Indian Immunologicals Limited, H1 2016 28 Diphtheria - Pipeline by LG Life Science LTD., H1 2016 29 Diphtheria - Pipeline by Panacea Biotec Limited, H1 2016 30 Diphtheria - Pipeline by Prometheon Pharma, LLC, H1 2016 31 Diphtheria - Pipeline by Sanofi Pasteur SA, H1 2016 32 Diphtheria - Pipeline by Serum Institute of India Limited, H1 2016 33 Diphtheria - Pipeline by Sinovac Biotech Ltd., H1 2016 34 Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Route of Administration, H1 2016 41 Number of Products by Stage and Molecule Type, H1 2016 43 Diphtheria Therapeutics - Recent Pipeline Updates, H1 2016 77 Diphtheria - Dormant Projects, H1 2016 79 Diphtheria - Discontinued Products, H1 2016 80
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.